Update on New and Emerging CD-20 Targeted Therapeutics for the Treatment of Patients with Multiple Sclerosis
Update on New and Emerging CD-20 Targeted Therapeutics for the Treatment of Patients with Multiple Sclerosis is organized by AcademicCME.
Program Dates: March 23, 2023 – March 22, 2024
Program Overview:
This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight new and emerging CD-20 targeted therapeutics for the treatment of patients with multiple sclerosis (MS). The expert faculty, Dr. Mark Freedman, will first review current clinical trial data for CD-20 targeted therapies to improve long-term patient outcomes. Following, Dr. Freedman will assess life-long treatment plans that include tools to monitor disease progression, and strategies to minimize physical and cognitive disability. Upon completion of this activity, learners will gain a better understanding of how to treat their patients with MS, utilizing CD-20 targeted therapeutics.
Learning Objectives:
• Review current clinical trial data for CD-20 targeted therapies to improve long-term patient outcomes.
• Update life-long treatment plans that include tools to monitor disease progression, and strategies to minimize physical and cognitive disability.